This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
FSCB Polyclonal Antibody
catalog :
PA5-51957
quantity :
100 uL
price :
US 474.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
immunohistochemistry, immunohistochemistry - paraffin section
product information
Product Type :
Antibody
Product Name :
FSCB Polyclonal Antibody
Catalog # :
PA5-51957
Quantity :
100 uL
Price :
US 474.00
Clonality :
Polyclonal
Purity :
Antigen affinity chromatography
Host :
Rabbit
Reactivity :
Human
Applications :
Immunohistochemistry (Paraffin): 1:200-1:500
Species :
Human
Isotype :
IgG
Storage :
Store at 4 C short term. For long term storage, store at -20 C, avoiding freeze/thaw cycles.
Description :
May be involved in the later stages of fibrous sheath biogenesis and spermatozoa capacitation. Inhibits ROPN1 and ROPN1L SUMOylation. Binds calcium. [UniProt]
Immunogen :
Recombinant protein corresponding to Human FSCB. Recombinant protein control fragment (Product # RP-89146 ).
Format :
Liquid
Applications w/Dilutions :
Immunohistochemistry (Paraffin): 1:200-1:500
Aliases :
C14orf155; EG623046; fibrous sheath CABYR binding protein; fibrous sheath CABYR-binding protein; FSCB; PKA phosphorylated calcium and CABYR-binding protein; PKA-phosphorylated calcium and CABYR-binding protein
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments
